Abstract
We report a 58-year-old woman with drug eruptions induced by the BCR-ABL tyrosine kinase inhibitor, Glivec®. One month after the beginning of administration of Glivec® (400 mg/day), multiple areas of erythema over the entire body with itching erupted. We obtained a biopsy specimen of the erythema and made the diagnosis of erythema exudative multiforme. We treated the patient with corticosteroid administration (betamethasone 0.5 mg/day) and reduced the dosage of Glivec® (200 mg/day). One month later, the erythema reappeared and hyperkeratosis with scales on the palms and soles appeared. Purpura on both legs followed in two months. DLST for Glivec® was negative. We also reported 4 other cases with drug eruptions induced by Glivec®.
